The Combined Deletion of S6K1 and Akt2 Deteriorates Glycemic Control in a High-Fat Diet

REFERENCES

• Aguilar V, et al. 2007. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab. 5:476–487.
   PubMedGoogle Scholar
• Alliouachene S, et al. 2008. Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. J. Clin. Invest. 118:3629–3638.
   PubMedGoogle Scholar
• Ayala JE, et al. 2010. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model. Mech. 3:525–534.
   PubMed Web of Science ®Google Scholar
• Carnevalli LS, et al. 2010. S6K1 plays a critical role in early adipocyte differentiation. Dev. Cell 18:763–774.
   PubMed Web of Science ®Google Scholar
• Cho H, et al. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728–1731.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.
   PubMed Web of Science ®Google Scholar
• Danial NN, et al. 2008. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14:144–153.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell. Biol. 29:5657–5670.
   PubMed Web of Science ®Google Scholar
• Espeillac C, et al. 2011. S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy. J. Clin. Invest. 121:2821–2832.
   PubMedGoogle Scholar
• Fraenkel M, et al. 2008. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945–957.
   PubMed Web of Science ®Google Scholar
• Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. 2001. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 98:9666–9670.
   PubMed Web of Science ®Google Scholar
• Harrington LS, et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213–223.
   PubMed Web of Science ®Google Scholar
• Harrison DE, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392–395.
   PubMed Web of Science ®Google Scholar
• Holz MK, Blenis J. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280:26089–26093.
   PubMed Web of Science ®Google Scholar
• Houde VP, et al. 2010. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338–1348.
   PubMed Web of Science ®Google Scholar
• Julien LA, Carriere A, Moreau J, Roux PP. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30:908–921.
   PubMed Web of Science ®Google Scholar
• Lamming DW, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638–1643.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. 2011. mTOR signaling. Cold Spring Harb. Perspect. Biol. 4:a011593. https://doi.org/10.1101/cshperspect.a011593.
   Google Scholar
• Lu M, et al. 2012. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18:388–395.
   PubMed Web of Science ®Google Scholar
• Lustig Y, et al. 2011. Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev. 25:1232–1244.
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261–1274.
   PubMed Web of Science ®Google Scholar
• Michael MD, et al. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6:87–97.
   PubMed Web of Science ®Google Scholar
• Ohanna M, et al. 2005. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7:286–294.
   PubMed Web of Science ®Google Scholar
• Pan KZ, et al. 2007. Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 6:111–119.
   PubMed Web of Science ®Google Scholar
• Panasyuk G, et al. 2012. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 3:672.
   PubMed Web of Science ®Google Scholar
• Pende M, et al. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408:994–997.
   PubMed Web of Science ®Google Scholar
• Reznick RM, et al. 2007. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 5:151–156.
   PubMed Web of Science ®Google Scholar
• Ruvinsky I, et al. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19:2199–2211.
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159–168.
   PubMed Web of Science ®Google Scholar
• Selman C, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326:140–144.
   PubMed Web of Science ®Google Scholar
• Shah OJ, Hunter T. 2006. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26:6425–6434.
   PubMed Web of Science ®Google Scholar
• Shima H, et al. 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17:6649–6659.
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85–96.
   PubMed Web of Science ®Google Scholar
• Treins C, Warne PH, Magnuson MA, Pende M, Downward J. 2010. Rictor is a novel target of p70 S6 kinase-1. Oncogene 29:1003–1016.
   PubMed Web of Science ®Google Scholar
• Um SH, et al. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205.
   PubMed Web of Science ®Google Scholar
• Vodenik B, Rovira J, Campistol JM. 2009. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant. Proc. 41:S31–S38.
   PubMedGoogle Scholar
• Yang SB, et al. 2011. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J. Mol. Med. (Berl). 90:575–585.
   PubMedGoogle Scholar
• Yoon JC, et al. 2003. Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev. Cell 5:73–83.
   PubMedGoogle Scholar
• Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21–35.
   PubMed Web of Science ®Google Scholar